We start English website service. Thank you for waiting this.
Improved HBV vaccine using the 3rd generation antigen L-HBsAg containing preS and S proteins
Hepatitis B is a serious infectious disease with WHO estimate of 2 billion infectees and 360 million chronic patients. Areas with higher risk of exposure to hepatitis B include Russia, Eastern Europe, India, China, LATAM, Africa and South East Asia.
CVI has developed two HBV vaccine projects, improved prophylactic HBV vaccine and therapeutic HBV vaccine using adjuvant, which are in clinical development stages. Having entire HBV surface antigen and Alum as adjuvant, CVI-HBV-001 can achieve higher titers of antibody response over the 2nd generation vaccines with only two injections, providing faster and enhanced immune responses.
Two dose vaccine can be developed
Potential target populations are non-responders and high risk groups
Rapid protection and higher antibody titers induced
In clinical trial, CVI-HBV-001 has induced rapid sero-protection and higher antibody titers with two immunizations, and also induced sero-protection in non-responder group.